The use of the Xevo™ TQ-MS combined with Waters UltraPerformance LC® (UPLC) technology increases BioFocus DPI ADME/PK Laboratory’s throughput and allows more accurate measurements to both quantify and confirm the identity of metabolites in a wide range of biological fluids and tissues. For molecules that would have a poor response using standard technologies, the Xevo™ TQ-MS will increase the likelihood of detection. In addition to bioanalysis, ADME/PK Laboratory offers high-quality services backed by expert consultancy - extending from discovery ADME to in vivo pharmacokinetics.
“We are building ADME/PK Laboratory’s advanced bioanalysis service to provide the best ADME data to support drug discovery programs for our UK, US and European clients,” said Chris Newton, SVP BioFocus DPI. “With this newly installed instrument providing greater sensitivity, accuracy and speed, we further enhance the service that we deliver - whether this is for a small scale study or as part of an integrated drug discovery program.”
About BioFocus DPI
BioFocus DPI aims to expand its partners’ drug pipelines by accelerating the gene-to-candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services. As the service division of Galapagos, BioFocus DPI has over 250 employees in four countries worldwide.
